Table 2.

APOE allele frequency in patients with AD and control subjects by center and odds ratios for developing AD according to the presence of the ε4 allele adjusted for sex, age, and center

Location of centernAllele frequencyOR (95% CI)
ε2ε3ε4ε4+ vs ε4−
OR = odds ratio.
Finland
    AD cases1090.070.720.213.4 (2.0–5.9)
    Controls1880.080.830.09p < 0.0001
UK
    AD cases2750.040.580.384.2 (3.0–6.5)
    Controls2030.080.780.14p < 0.0001
France
    AD cases6750.040.610.355.3 (4.2–6.8)
    Controls6570.070.820.11p < 0.0001
Spain
    AD cases1160.030.600.3711.6 (6.2–21.7)
    Controls1330.050.880.07p < 0.0001
Minnesota, USA
    AD cases2960.040.620.344.0 (2.9–5.4)
    Controls4630.100.780.12p < 0.0001
St. Louis, Missouri, USA
    AD cases2610.030.650.323.7 (2.5–5.3)
    Controls2820.080.800.12p < 0.0001
Total
    AD cases1,7320.040.620.344.6 (4.0–5.3)
    Controls1,9260.080.810.11p < 0.0001